Davis JC et al. – Significant advances have occurred of the pathophysiology, diagnosis, and classification of the spondyloarthritides (SpA) and effective treatments are available. Methods
The aim of this review was to evaluate the classification, genetic susceptibility, pathology, and response to treatment of SpA
Searches were conducted of the PubMed database
Results
The 5 subsets of SpA share many clinical, IHC, and genetic features, including the presence of human leukocyte antigen-B27 and the absence of RF
Pathology of SpA is mediated by immune cells
TNF-α appears to be an important driver of inflammation and damage in SpA
A number of different SpA classification criteria have been developed
Suboptimal efficacy and adverse effects often limit the use of conventional pharmacologic treatments for SpA, including NSAIDs and DMARDs
Targeted biologic response modifiers, such as TNF-α antagonists, are well tolerated and efficacious treatments for SpA
See all
